CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Magnetic Esophageal Sphincter Augmentation to Treat Gastroesophageal Reflux

This policy governs coverage for laparoscopically implanted magnetic esophageal sphincter augmentation devices (eg, LINX) to treat gastroesophageal reflux disease (GERD) for Blue Cross Blue Shield - Rhode Island members.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyMagnetic Esophageal Sphincter Augmentation to Treat Gastroesophageal Reflux

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJan 1, 2017

Next Review DateN/A

Key ActionVerify member benefits and document eligibility through the member's contract before billing, as coverage may vary and the procedure is stated as not covered.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not coveredCoverage stance

43284Procedure code

FDA-approvedDevice status

02/06/2020Last update

Coverage determination

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Overall coverage determination

Covered when ALL of the following are met:

Main coverage stance: Magnetic esophageal sphincter augmentation to treat gastroesophageal reflux disease is not covered / not medically necessary because the evidence is insufficient to determine effects on health outcomes.

Applies to commercial lines; see member benefits for variability.

What providers must do

Prior Authorization

Prior authorization: Not applicable for medical criteria/prior authorization. Benefit verification is required prior to scheduling services to confirm member coverage and any applicable cost sharing.

Prior authorization: Not required

Note

Therapy Context

Device is intended for patients with gastroesophageal reflux disease (GERD) who continue to have symptoms despite maximum medical therapy. This policy addresses insertion of the magnetic esophageal sphincter augmentation device only; refer to related policy for device removal.

Therapy context: For patients with GERD despite maximal medical therapy
Policy scope: Insertion only — removal addressed in related policy

Documentation Required

Benefit Verification and Documentation

Benefits vary by contract. Providers must verify member eligibility and benefits (including medical necessity and coverage of this procedure) with the member's benefit booklet, Evidence of Coverage, or Subscriber Agreement before performing services. Document clinical indications, prior treatments (including trials of maximal medical therapy and proton pump inhibitor use), and rationale for the procedure in the medical record to support claims.

Benefit verification: Check member-specific Benefit Booklet / Evidence of Coverage / Subscriber Agreement
Documentation: Record prior medical therapy, symptoms, and justification in the medical record
Provider contact: Call BCBSRI provider call center for member-specific benefits information

Denial Risk

Denial Risk — Noncovered Procedure

Claims for CPT 43284 (laparoscopic placement of magnetic esophageal sphincter device) may be denied as not covered or not medically necessary per this policy.

Affected code: CPT 43284 — may be denied/not covered

Clinical background

Gastroesophageal reflux disease (GERD) is the reflux of stomach acid into the esophagus causing symptoms and/or mucosal injury and affects a substantial proportion of the population. The LINX magnetic sphincter augmentation system is a laparoscopically implanted band of interlinked titanium beads with magnetic cores placed at the gastroesophageal junction intended to augment the lower esophageal sphincter and reduce reflux for patients with persistent symptoms despite maximal medical therapy. Current policy concludes the available evidence is insufficient to determine whether magnetic sphincter augmentation improves health outcomes for GERD.

Device definition

Magnetic sphincter augmentation (MSA) / LINX Reflux Management System — device description and regulatory note

Device descriptionLINX Reflux Management System: a laparoscopically implanted flexible band of 10–18 interlinked titanium beads with magnetic cores placed around the esophagus at the gastroesophageal junction to augment the lower esophageal sphincter and reduce reflux; swallowing transiently separates beads to allow passage of food.

Intended populationPatients with GERD who continue to have chronic symptoms despite maximum medical therapy (eg, proton pump inhibitors) and who are candidates for a less invasive option than fundoplication.

Removability and MRI noteThe device can be removed laparoscopically if severe adverse events occur or if magnetic resonance imaging is needed for another condition.

Regulatory statusFDA premarket approval (2012) for treatment of GERD in patients with abnormal pH testing who continue to have chronic symptoms despite maximum therapy; FDA product code LEI.

Potential adverse eventsReported adverse events may include dysphagia or odynophagia; evidence includes single-arm trials and observational studies with limited comparative data.